INCY
Incyte Corporation (INCY) Q1 2026 Earnings Call
Incyte Corporation (NASDAQ: INCY) Q1 2026 Earnings Conference
Incyte Corporation (INCY) Q1 2026 Earnings Announcement
Incyte Corporation (NASDAQ: INCY) Q1 2026 Earnings Announcement
Incyte Corporation (INCY) Sec Form 8K
Incyte Corporation (NASDAQ: INCY) Sec Form 8K
Incyte Corporation (INCY) Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Incyte Corporation (NASDAQ: INCY) FY 2026 Other Release
Incyte Corporation (INCY) Sec Form 8K
Incyte Corporation (NASDAQ: INCY) Sec Form 8K
Incyte Corporation (INCY) Incyte Announces Executive Leadership Appointments
Incyte Corporation (NASDAQ: INCY) FY 2026 Management Update
Incyte Corporation (INCY) Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Incyte Corporation (NASDAQ: INCY) FY 2026 Other Release
Incyte Corporation (INCY) Q4 2025 Earnings Call Transcript
Incyte Corporation (NASDAQ: INCY) Q4 2025 Earnings Call dated Feb. 10, 2026 Corporate Participants: Alexis Smith — Vice President &…
Incyte Corporation (INCY) Sec Form 8K
Incyte Corporation (NASDAQ: INCY) Sec Form 8K
Incyte Corporation (INCY) Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
Incyte Corporation (NASDAQ: INCY) FY 2026 Other Release